|
Patent landscape, scope, and claims: |
Scope and Claims of US Patent 7,351,401: Amyloid Binding Radiolabeled Compounds and Imaging/Detection Methods
Executive summary: US 7,351,401 claims a broad class of amyloid-binding small molecules defined by a shared heterocycle “Z” motif, with extensive substituent latitude (R1-R10 and related ring/sidechain groups) and explicit coverage of radiolabeled variants (I-131/I-123/F-18/Br-75/Br-76/C-11/C-14/C-13) and chelated metal complexes (Tc/Re; and “with chelated metal group” constructs). The estate also claims downstream use: (1) pharmaceutical imaging compositions, (2) in vivo detection of amyloid deposits including brain targeting and PET/SPECT gamma imaging, and (3) ex vivo/tissue workflows including formalin-fixed/fresh-frozen incubation and microscopy-based detection, plus quantitative assays in homogenates. The claim set is structured to (i) capture multiple payload modalities (direct radionuclides, carbon labeling, and chelator-metal complexes), (ii) support multiple imaging readouts (gamma imaging, MRI/MRS listed, microscopy techniques listed), and (iii) preserve infringement leverage through method claims that track binding to amyloid deposits rather than disease-specific biomarkers.
What does US 7,351,401 claim: amyloid binding radiolabeled compounds and salts?
Core claim scope (Claim 1)
Claim 1 covers: “An amyloid binding compound” defined by a formula with:
- a heterocycle linkage parameter Z selected from S, NR′, O, or CR′, with a tautomer constraint when Z = CR′ (“correct tautomeric form… is an indole” and **R′ is H or lower alkyl”).
- a ring/sidechain linkage parameter Y selected from NR1R2, OR2, or SR2, with a constraint that the corresponding nitrogen “is not a quaternary amine.”
- broad substituent definitions for R1, R2, and R3-R10 with:
- generic organic substituent options (H, lower alkyl, CF3, halomethyl/haloalkyl motifs, cyano, nitro, carbonyl-containing groups, anilide/phenyl-like groups labeled “Rph” and substituted variants),
- explicit allowance for tri-alkyl tin,
- explicit allowance for chelating groups of the form W-L or V-W-L (with or without a chelated metal group),
- explicit allowance for radiolabel-bearing substitutions where at least one substituent among R3-R10 is a listed radionuclide (I-131/I-123/I-125, Br-75/Br-76, F-18) or carbon radiolabel (C-11/C-13/C-14),
- explicit allowance for Tc/Re-chelated complexes through L and M\ constructs (Tc and Re; and specifically M* = 99mTc in one branch).
Salt coverage
Claim 1 also covers water soluble, non-toxic salts of the amyloid binding compounds. That phrase gives formulators room to argue salt-form infringing equivalents where the base compound is used for imaging.
How broad is the structural coverage via variable substituents (R1-R10)?
The patent uses the common “Markush-style” approach: the claim is anchored to the core heterocycle design, then supplies exceptionally large combinatorial freedom for substituents:
- R1 and R2 independently selected from a long list including multiple heteroalkoxy/alkoxy and haloalkyl options; phenyl (“Rph”) and substituted phenyls; carbonyl and cyano; tin; and chelating group moieties.
- R3-R10 independently selected from a similar list, including chelating constructs and radiolabel options.
This is not a narrow “one compound” claim. It is a family claim for amyloid binders, including radiolabeled embodiments and chelated radionuclide embodiments.
Radiolabel scope inside Claim 1
Claim 1 explicitly lists payloads that convert structural variants into imaging agents:
- Direct radionuclides among R3-R10: 131I, 125I, 123I, 76Br, 75Br, 18F, and 19F (with 19F showing as an allowed substituent category, while 18F is singled out as radioactive).
- Carbon radiolabel substituents: a “carbon-containing substituent” that includes lower alkyl and other carbon-containing groups where “at least one carbon is 11C, 13C or 14C.”
- Chelating group with chelated metal:
- Tc and Re via M = Tc/Re, and another branch where M* = 99mTc.
- The claim contains multiple alternate chelator-metal structures via L and L* blocks, with V selected from –COO–, –CO–, –CH2O–, –CH2NH– and W selected as a polymethylene linker of variable length.
Key structural constraints that limit “outsiders”
Even with broad freedom, the claim includes several limiting constraints:
- Z tautomer/indole condition when Z = CR′.
- Y nitrogen not quaternary.
- Several branches define radiolabel placement “at least one substituent R3-R10 is selected from…” which can matter for design-arounds that move payload to a position not covered by R3-R10.
Which dependent claims narrow the radiolabel and substitution patterns?
Radiolabel narrowing
- Claim 2: where the radiolabel of one of R3-R10 is selected from 131I, 125I, 123I, 76Br, 75Br, 18F, 19F.
- Claim 3: where the radiolabel is 11C and 18F.
These dependent claims reduce arguments about whether the payload must be among the enumerated radioisotopes.
Specific substitution embodiments (Claims 4-15)
Claims 4-15 define multiple narrower exemplars with exact combinations of Z, Y, R′, R1/R2, and a “most R3-R10 are H” pattern in several places. Examples:
- Claim 4: Z = S; Y = N; R1 = H; R2 from a subset (includes alkoxyalkyl, CF3, haloalkyl, carbonyl, phenyl). It includes a conditional limitation: “wherein when R2 is CH2Rph R8 is not CH3.”
- Claim 5: Z = S; Y = N; R′ = H; R2 = CH3; and R3-R10 are H.
- Claim 6: Z = S; Y = O; R′ = H; R2 = CH3; and R3-R10 are H.
- Claim 7: Z = S; Y = N; R′ = H; R1-R4 = H; R5 = I; and R6-R10 are H.
- Claims 8-12: encode additional constraints including R8OH and/or specific haloalkyl substitutions like R2 = CH2-CH2-CH2-F (Claim 9) or R2 = CH2-CH2-F (Claim 10), with remaining groups H except specified ones.
- Claim 13: in Claim 4, at least one of R3-R10 is from CN, OCH3, OH, NH2.
- Claims 14-15: specify combinations for R1/R2/R8 and then constrain which groups remain H.
Claim 16-21
Claims 16-21 are “having the structure:” claims, which typically lock in specific disclosed structures (text for the structures is omitted in the provided claim block), but their presence indicates the specification includes concrete compounds that are formally claimed alongside the broader Markush family.
What imaging and detection methods are claimed in US 7,351,401?
The estate includes composition and method claims that map directly to commercial use-cases for amyloid imaging agents, with both in vivo and ex vivo workflows.
Pharmaceutical compositions (Claims 23-24)
- Claim 23: pharmaceutical composition for in vivo imaging of amyloid deposits comprising:
- (a) compound of Claim 1
- (b) pharmaceutically acceptable carrier.
- Claim 24: similar but with an added limitation that Z = S, Y = N, R1 = H for the compound component.
In vivo detection (Claims 25-31)
- Claim 25: in vivo method for detecting amyloid deposits:
- administer detectable quantity of composition of Claim 23,
- detect binding of the compound to amyloid deposit.
- Claim 26: amyloid deposit in brain.
- Claim 27: patient suspected of Alzheimer’s disease, familial Alzheimer’s disease, Down’s syndrome, or APOE4 homozygotes.
- Claim 28: detecting selected from gamma imaging, magnetic resonance imaging, magnetic resonance spectroscopy.
- Claim 29: when gamma imaging is used, it is PET or SPECT.
- Claim 30: composition administered by intravenous injection.
- Claim 31: detect a ratio of binding:
- (i) binding to brain area other than cerebellum
- to (ii) binding to cerebellum,
compared to ratios in normal subjects.
This ratio claim is a meaningful technical peg for litigator and expert analysis because it ties detection to an interpretation metric rather than only “binding exists.”
Tissue methods (Claims 32-36)
- Claim 32: detecting amyloid in biopsy or post-mortem tissue:
- incubate formalin-fixed or fresh-frozen tissue with a solution of compound of Claim 1 to form a labeled deposit,
- detect labeled deposits.
- Claim 33: depends from Claim 32 and adds radiolabeled-solution detail:
- solution is 25-100% ethanol with the remainder water,
- saturated with an amyloid binding compound of the formula (with extensive recitation of the Claim 1 formula and radiolabel/chelator latitude).
- Claim 34: depends from Claim 32 and specifies:
- aqueous buffer containing 0-50% ethanol
- compound concentration 0.0001 to 100 μM.
- Claim 35: detection via microscopy techniques:
- bright-field, fluorescence, laser-confocal, cross-polarization.
- Claim 36: quantifying amyloid amount:
- incubate radiolabeled compound of Claim 1 with tissue homogenate,
- separate tissue-bound from tissue-unbound,
- quantify bound compound,
- convert to micrograms amyloid per 100 mg tissue using a standard.
Claim 36’s measurement workflow is commercially relevant because it can capture kit-like assay methods and lab protocols if infringement turns on “use” rather than just compound manufacture.
How does Claim 1 structure infringement risk for competitors (direct radionuclide vs chelator vs carbon label)?
Three payload pathways are claimed
- Directly radiolabeled substituents (I, Br, F) embedded among R3-R10.
- Carbon radiolabeling on carbon-containing substituent moieties (C-11/C-13/C-14).
- Chelated metal complexes using Tc/Re (including 99mTc) via L/L* blocks.
That means a competitor cannot avoid risk by switching radionuclides alone; the claim still attempts to capture multiple radionuclide classes through different claim branches.
Where competitors may attempt design-arounds
Claim scope is anchored to:
- Z and Y selection,
- the Markush substituent universe, and
- radiolabel placement “at least one of R3-R10…”
A plausible design strategy (conceptually) is to use the same core amyloid-binding scaffold but change:
- which substitution positions bear the payload,
- the chelator architecture so it does not match the specific W-L / V-W-L / W-L / V-W-L definitions, or
- the “Z tautomeric/indole” condition if Z is engineered away from the constrained set.
However, as drafted, Claim 1 is written to include extensive payload flexibility, so many substitutions still land inside the enumerated families.
How strong is the patent estate for enforcement: scope breadth vs definitional constraints
Strength from breadth
- The compound claim is family-wide with large substituent freedom.
- It explicitly covers multiple radionuclides and carbon label variants.
- It includes both composition and method claims, creating multiple potential infringement routes:
- direct compound use/manufacture,
- formulation into an imaging composition,
- clinical in vivo detection workflows,
- ex vivo/tissue incubation, microscopy detection, and quantification workflows.
Strength from additional interpretive method claims
- Claim 31 adds a specific binding ratio comparison (non-cerebellum to cerebellum) which can be used as a “procedure hook” for infringement allegations tied to readout protocols.
Potential constraint points
- The claim includes several hardwired structural choices (Z set, Y set, indole tautomer condition, nitrogen not quaternary).
- Some dependent claims specify very narrow patterns, but those dependents mainly provide fallback positions.
What generic entry risks exist for amyloid imaging radiotracers under this patent?
Radiopharmaceutical “generic entry” is unlike small-molecule tablets: there is usually no Orange Book pathway in the same way for individualized radiolabels, but there can be competitive equivalents via:
- alternative radionuclides or labeling methods,
- alternative chelators,
- formulation changes,
- and alternative imaging readouts.
Under this patent, the major entry risks are:
- Compound-level risk: if the radiolabeled compound still falls within the Markush definitions and radiolabel placement is within the claimed R3-R10 positions or within chelator definitions.
- Method-level risk: even if the compound is licensed/changed, labs or clinics performing the claimed tissue incubation/detection quantification workflows could still be exposed if the administered/used compound is within Claim 1.
How do the claimed imaging modalities affect design-around strategy?
The method claims include:
- in vivo: binding detection, brain targeting, suspected disease categories, PET/SPECT, MRI/MRS listed, and IV injection.
- ex vivo: formalin-fixed/fresh-frozen incubations, ethanol/aqueous buffer protocols, microscopy techniques, and quantification by homogenate binding separation and standard conversion.
A competitor that tries to avoid infringement by changing clinical imaging route still faces risk because:
- PET/SPECT is explicitly claimed.
- microscopy methods are explicitly claimed for tissue workflows.
- even “detecting binding” language is broad and can be satisfied by many amyloid imaging operational frameworks if they use the claimed compounds.
Key Takeaways
- US 7,351,401 Claim 1 is a broad amyloid-binding scaffold family with extensive substituent latitude and explicit coverage of radiolabels including I-131/I-123/Br-75/Br-76/F-18 plus C-11/C-13/C-14, and chelated Tc/Re including 99mTc.
- Dependent claims narrow radiolabel choices and provide specific substitution exemplars, including embodiments where many R3-R10 groups are H, helping the patentee capture more specific commercial candidates.
- The patent adds enforceable downstream coverage: imaging compositions, in vivo amyloid detection (brain targeting; PET/SPECT; IV injection; cerebellum normalization ratio), and ex vivo formalin-fixed/frozen tissue workflows including ethanol/buffer incubation, microscopy detection modes, and quantitative homogenate assay steps.
- Competitive exposure is multi-route: manufacture/use of the radiolabeled compounds and performance of clinical or lab detection workflows can both trigger infringement.
FAQs
-
Can switching from iodine to fluorine avoid infringement of US 7,351,401?
No, Claim 1 explicitly includes multiple radionuclides (including I-131/I-123 and F-18) and also supports carbon label variants and Tc/Re-chelated forms.
-
Does the patent cover both PET/SPECT and MRI/MRS detection methods?
Yes. In vivo method Claim 28 lists gamma imaging plus MRI and MRS, and Claim 29 specifies PET or SPECT for the gamma imaging subset.
-
Are tissue incubation and microscopy-based amyloid detection workflows protected?
Yes. Claims 32-35 cover incubation of formalin-fixed or fresh-frozen tissue with the compound solution and detection including microscopy modalities.
-
Is a cerebellum normalization or binding ratio required for infringement?
Only for the specific ratio method claim (Claim 31). Other in vivo detection claims require binding detection but not the ratio.
-
Do chelated Tc/Re radiolabel versions fall within the compound claim?
Yes. Claim 1 defines chelating groups (W-L/V-W-L and L*) with Tc/Re, including 99mTc in one branch.
References
- United States Patent 7,351,401. “Amyloid binding radiolabeled compounds and methods for imaging and detecting amyloid deposits.” (Claims provided in user input).
More… ↓
⤷ Start Trial
|
